ARTIVION, INC.

# Signal Note: Perceptive Advisors Initiates $78.6M AORT Position Perceptive's entry into Artivion, a cardiovascular device company, signals confidence in its regenerative tissue portfolio—likely driven by near-term clinical or commercial catalysts in its core aortic repair franchises (including the Cardiac Biostability Platform) or recent M&A optionality. Edelman's track record favors clinical-stage value creation, though AORT is primarily device/tissue-based rather than traditional drug development, suggesting he sees underappreciated assets or valuation dislocation. Key catalysts to monitor: FDA decisions on regenerative tissue claims, hospital adoption metrics, or potential strategic transactions.